Cullgen Inc. Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Cullgen Inc. is a San Diego, California-based biotechnology company pursuing targeted protein degradation. Its uSMITE platform harnesses the cell's ubiquitin-proteasome system to selectively eliminate disease-causing intracellular proteins, including a large portion often deemed undruggable by conventional small molecules. The company is advancing its own pipeline while also developing a portfolio of novel E3 ligands to expand its therapeutic modalities.

Operating in the biotechnology research industry, Cullgen positions itself as a developer of protein degraders intended to broaden the range of addressable disease targets. Its customers are researchers and biopharmaceutical developers seeking new approaches to intracellular proteins that lack effective therapeutic options. In March 2026, Gyre Therapeutics announced an agreement to acquire Cullgen in an all-stock transaction.

Sign up for free to view info

Company overview Employee directory